Jiménez-Rubio G, Bellon Velasco A, Ortíz–López L, Ramírez-Rodríguez G, Ortega-Soto H, Benítez-King G

Language: Spanish
References: 77
Page: 1-10
PDF size: 104.53 Kb.

ABSTRACT

Postmortem and neuroimaging studies of Major Depressive Disorder patients have revealed changes in brain structure. In particular the reduction in prefrontal cortex and in hippocampus volume has been described. In addition, a variety of cytoarchitectural abnormalities have been described in limbic regions of major depressive patients. Decrease in neuronal density has been reported in the hippocampus, a structure involved in declarative, spatial and contextual memory. This structure undergoes atrophy in depressive illness along with impairment in cognitive function.
Several studies suggest that reduction of hyppocampus volume is due to the decreased cell density and diminished axons and dendrites.
These changes suggested a disturbance of normal neuronal polarity, established and maintained by elements of the neuronal cytoskeleton. In this review we describe evidence supporting that neuronal cytoskeleton is altered in depression. In addition, we present data indicating that the cytoskeleton can be a potential target in depression treatment.
Neurons are structural polarized cells with a highly asymmetric shape. The cytoskeleton plays a key role in maintain the structural polarization in neurons which are differentiated in two structural domains: The somato-dendritic domain and the axonal domain. This differentiated asymmetric shape, depends of the cytoskeletal organization which support, transport and sorts various molecules and organelles in different compartments within the cell. Microtubules determine the asymmetrical shape and axonal structure of neurons and form the tracks for intracellular transport, of crucial importance in axonal flux. Actin microfilaments are involved in force generation during organization of neuronal shape in cellular internal and external movements and participate in growth cone formation. This important cytoskeletal organization preceed the formation of neurites that eventually will differentiated into axons or dendrites, a process that also comprises a dynamic assembly of the three cytoskeletal components. Intermediate filaments are known in neurons as neurofilaments spatially intercalated with microtubules in the axons and facilitate the radial axonal growth and the transport. Neurofilaments also act supporting other components of the cytoskeleton. All changes and movements of the cytoskeletal organization are coordinated by cytoskeletal associated proteins such as the protein tau and the microtubule associated proteins (MAPs). Also, specific interactions of microfilaments, microtubules and filaments which are regulated by extracellular signals take place in modulation of the cytoskeletal rearrangements.
The polarized structure and the highly asymmetric shape of neurons are essentials for neuronal physiology and it appears to be lost in patients with a Major Depressive Disorder. Histopathological studies have shown that the hippocampus and frontal cortex of patients with major depressive disorder have diminished soma size, as well as, have decreased dendrites and cellular volume.
Dendrite formation depends mainly in microfilaments organization as well as in polarization of the microtubule binding protein MAP2. In addition, there is a decreased synaptic connectivity and an increased oxidative stress, which originates abnormalities in the cytoskeletal structure. These neuronal changes originate alterations in the brain functionality such as decreased cognitive abilities and affective dis-regulations, usually encountered in patients with depression. Therefore, pathologic lesions implicating an altered cytoskeletal organization, may have an important role in decreased cognitive functions, observed in depression, as well as in changes in the brain volume, explained by a lost of neuronal processes such as axons, dendrite processes or dendritic spines, rather than by loss of neuronal or glial cell bodies. This explanation is supported by light immunomicroscopy of brain slices postmortem stained with specific antibodies.
Psychological stress which causes oxidative stress has also been suggested to cause a decrease of neuronal volume in the prefrontal cortex, altering the synaptic connections established with the hippocampus. This conclusion was drawn from studies in animal models of psychological stress associated with molecular measurements where defects in the expression of MAP1 and sinaptophysin were found, suggesting that defects in cytoskeletal associated proteins could underlie some cytoarchitectural abnormalities described in depression. Together all the evidence accumulated indicates that major depression illness and bipolar depression are mental disorders that involve loss of axons and dendrites in neurons of the Central Nervous System, that in consequence cause disruption of synaptic connectivity. Thus is possible that depression can be considered as a cytoskeletal disorder, therefore this cellular structure could be a drug target for therapeutic approaches by restoring normal cytoskeleton structure and precluding damage caused by oxygen-reactive species.
In this regard, melatonin, the hormone secreted by pineal gland during dark phase of the photoperiod, has two important properties that can be useful in treatment of mental disorders. First, the melatonin is a potent free-radical scavenger and second this hormone governs the assembly of the three main cytoskeletal components modulating the cytoskeletal organization. This notion is supported by direct action of melatonin effects on cytoskeletal organization in neuronal cells. In N1E-115 neuroblastoma cells, melatonin induced a two-fold increase in number of cells with neurites 1 day after plating; the effect lasting up to 4 days. Induction of neurite outgrowths is optimal at 1 nM melatonin and in presence of hormone the cells grew as clusters with long neurites forming a fine network to make contact with adjacent cells. Immunofluorescence of N1E-115 cells cultured under these conditions showed tubulin staining in long neurite processes connecting cells to each other. Neurite formation is a complex process that is critical to establish synaptic connectivity. Neuritogenesis takes place by a dynamic cytoskeletal organization that involves microtubule enlargement, microfilament arrangement, and intermediate-filament reorganization.
In particular, it is known that vimentin intermediate filaments are reorganized during initial stages of neurite outgrowth in neuroblastoma cells and cultured hippocampal neurons. Evidence has been published indicating that increase in microtubule assembly participates in neurite formation elicited by melatonin antagonism to calmodulin. Moreover, recently it was reported that melatonin precludes cytoskeletal damage produced by high levels of free radicals produced by hydrogen peroxide, as well as, damage caused by higher doses of the antypsychotics haloperidol and clozapine. N1E-115 cells incubated with either 100 uM hydrogen peroxide, 100 uM haloperidol, or 100 uM clozapine undergo a complete cytoskeletal retraction around the nucleus. By contrast, NIE-115 cells incubated with hydrogen peroxide, clozapine, or haloperidol followed by the nocturnal cerebrospinal fluid concentration of melatonin (100 nM) showed a well preserved cytoskeleton and neuritogenesis. Thus melatonin is a neuroprotective compound, since protects the neurocytoskeletal organization against damage caused by high concentrations of antipsychotics and oxidative stress.
As mentioned previously, polarity is intrinsic to neuronal function.
In neurons, somatodendritic domain receives and decodes incoming information and axonal domain delivers information to target cells. Progressive loss of neuronal polarity is one of the histopathologic events in depression. Cytoskeletal collapse underlie the lost of structural polarity and it is known that precede neuronal death and disappearance of synaptic connectivity. Drugs that prevent the loss of polarity and cytoskeleton retraction intrinsic to these diseases, as well as damage in cytoskeletal structure produced by oxidative stress can be extremely useful in depression treatment.
Melatonin is a potent free-radical scavenger that also acts as a cytoskeleton regulator; thus, we speculate that this hormone could be useful in prevention and alleviation of psychiatry diseases with synaptic connectivity disruption. Clinical trials show that melatonin administration is followed by alleviation of circadian disturbances and cognitive function in various neuropsychiatry diseases. Moreover, in depression, melatonin improves sleep. Thus, as suggestive as this information appears, controlled clinical trials will be necessary to investigate the beneficial effects of melatonin and other drugs in the depression treatment.

REFERENCES

1. ALONSO R, GRIEBEL G, PAVONE G, STEMMELIN J y cols.: Blockade of CRF (1) or V (1b) receptors reverses stressinduced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry, 9:278–286, 2004.

2. ANDRADE L, CARAVEO-ANDUAGA JJ, BERGLUND P, BIJL RV y cols.: DE The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res, 12:3–21, 2003.

3. BELLON A, ORTIZ-LOPEZ L, RAMIREZ-RODRIGUEZ G, ANTON-TAY F, BENITEZ-KING G: Melatonin induces neuritogenesis at early stages in N1E-115 cells through actin rearrangements via activation of protein kinase C and Rho-associated kinase. Pineal Research (en prensa), 2006.

4. BENITEZ-KING G, ANTON-TAY F: The role of melatonin in cytoskeletal remodeling is mediated by calmodulin and protein kinase C. Front Horm Res, 21:154-159, 1996.

5. BINDER LI, FRANKFURTER A, REBHUN LI: The distribution of tau in the mammalian central nervous system. J Cell Biol, 101:1371-1378, 1985.

6. BROWN J, COOPER-KUHN CM, KEMPERMANN G, VAN PRAAG H y cols.: Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci, 17:2042–2046, 2003.

7. CHANA G, LANDAU S, BEASLEY C, EVERALL PI, COTTER D: Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: Evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry, 53:1086-1098, 2003.

8. CHILDS PA, RODIN I, MARTIN NJ, ALLEN NH y cols.: Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. Br J Psychiatry, 166:196–198, 1995.

9. CID-ARREGUI A, DE HOOP M, DOTTI CG: Mechanism of neuronal polarity. Neurobiol Aging, 16:239-243, 1995.

10. COE C, KRAMER M, CZEH B, GOULD E y cols.: Prenatal stress diminishes neurogenesis in the dentate gyrus of juvenile rhesus monkeys. Biol Psychiatry, 54:1025–1034, 2003.

11. CZEH B, MICHAELIS T, WATANABE T, FRAHM J y cols.: Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Nat Acad Sci USA, 98:12796–12801, 2001

12. DEMISCH K, DEMISCH, L, BOCHNIK HJ, ALTHOFF PH y cols.: Melatonin and cortisol increase after fuvoxamine. Br J Clin Pharmacol, 22:620–622, 1986.

13. DEMISCH K, DEMISCH L, NICKELSEN T, RIETH R: The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine. J Neural Transm, 68:257–70, 1987.

14. DREVETS WC, PRICE JL, SIMPSON JR Jr, TODD RD y cols.: Subgenual prefrontal cortex abnormalities in mood disorders. Nature, 386:824–827, 1997.

15. DUMAN RS: Depression: A case of neuronal life and death? Biol Psychiatry, 56:140–145, 2004.

16. DUMAN RS, MALBERG J, THOME J: Neural plasticity to stress and antidepressant treatment. Biol Psychiatry, 46:1181- 1191, 1999.

17. ENCINAS MJ, VAAHTOKARI A, ENIDOLOPOV G: Fluoxetine targets early progenitor cells in the adult brain. PNAS, 103:8233-8238, 2006.

18. FRAZER A, BROWN R, KOCSIS J y cols.: Patterns of melatonin rhythms in depression. J Neural Transm, 21:269–90, 1986.

19. FUJIOKA T, FUJIOKA A, DUMAN RS: Activation of cAMP signaling facilitates the morphological maturation of newborn neurons in adult hippocampus. J Neurosci, 24:319–328, 2004.

20. GALEA LAM, MCEWEN BS, TANAPAT P, DEAK T y ciks,: Sex differences in dendritic atrophy of CA3 pyramidal neurons in response to chronic restraint stress. Neuroscience, 81:689–697, 1997.

21. GOLD P, CHROUSOS GP: Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol Psychiatry, 7:254–275, 2002.

22. HÄRTTER S, WANG X, WEIGMANN H, FRIEDBERG T y cols.: Differential Effects of Fluvoxamine and Other Antidepressants on the Biotransformation of Melatonin. J Clin Psychopharm, 21(2):167-174, 2001.

23. HAUGLAND RP, YOU W, PARAGAS VB, WELLS S y cols.: Simultaneos visualization of G- and F-Actin. J Histochem Cytochem, 42:345-350, 1994.

24. HAYES TL, LEWIS DA: Hemispheric differences in layer pyramidal neurons of the anterior language areas. Arch Neurol, 50:501-505, 1993.

25. HELFAND BT, MENDEZ MG, PUGH J, DELSERT C y cols.: A role for intermediate filaments in determining and maintaining the shape of nerve cells. Mol Biol Cell, 14:5069- 5081, 2003.

26. HELLSTEN, WENNSTROM M, BENGZON J, MOHAPEL P, TINGSTROM A: Electroconvulsive seizures induce endothelial cell proliferation in adult rat hippocampus. Biol Psychiatry, 55:420-427, 2004.

27. HOSSEIN FS, LAURENCE AJ, ARAGHI-NIKNAM M, STARY MJ y cols.: Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophrenia Research, 69(2-3):317-323, 2004.

28. JIMENEZ–RUBIO G, BENITEZ-KING, G, ORTIZ-LOPEZ L: Melatonin elicits neuritogenesis and reverses tau hyperphosphorylation in N1E-115 neuroblastoma cells treated with okadaic acid. En: Frank Columbus (ed). Focus in Neuroblastoma Research. Nova Science Publishers, Inc, Hauppauge (en prensa), 2007.

29. KAIDANOVICH-BEILIN O, MILMAN A, WEIZMAN A, PICK GC, ELDAR-FINKELMAN H: Rapid antidepressivelike activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus. Biol Psychiatry, 55:781-784, 2004.

30. LAMBERT KL, BUCKELEW SK, STAFFISO-SANDOZ G, GAFFGA S y cols.: Activity-stress induces atrophy of apical dendrites of hippocampal pyramidal neurons in male rats. Physiol Behav, 65:43–49, 1998.

31. LEMAIRE V, KOEHL M, LE MOAL M, ABROUS DN: Prenatal stress produces learning deficits associated with an inhibition of neurogenesis in the hippocampus. PNAS, 97:11032–11037, 2000.

32. LINK W, KONIETZKO U, KAUSELMANN G, KRUG M, SCHWANKE B, FREY U, KUHL D: Somatodendritic expression of an immediate early gene is regulated by synaptic activity. Proc Natl Acad Sci USA, 92:5734–5738, 1995.

33. LOPEZ JF, AKIL H, WATSON SJ: Neural circuits mediating stress. Biol Psychiatry 46:1461–1471, 1999.

34. LUCAS FR, SALINAS PC: WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Dev Biol, 192:31-44, 1997.

35. LUO L: Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. Rev Cell Dev Biol, 18:601-635, 2002.

36. MADSEN T, TRESCHOW A, BENGZON J, BOLWIG TG y cols.: Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry, 47:1043–1049, 2000.

37. MAGARIÑOS AM, MCEWEN BS: Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: comparison of stressors. Neuroscience, 69:83–88, 1995a.

38. MAGARIÑOS AM, MCEWEN BS: Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience, 69:89–98, 1995b.

39. MALBERG J, DUMAN RS: Cell proliferation in adult hippocampus is decreased by inescapable stress: Reversal by fluoxetine treatment. Neuropsychopharmacology, 28:1562–1571, 2003.

40. ALBERG J, EISCH AJ, NESTLER EJ, DUMAN RS: Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J Neurosci, 20:9104–9110, 2000.

41. MANJI HK, CHEN G, HSIAO JK, MASANA MI y cols.: Regulation of signal transduction pathways by mood stabilizing agents: Implications for the pathophysiology and treatment of bipolar affective disorder. En: Manji HK, Bowden CL, Belmaker RH (eds). Bipolar Medications: Mechanisms of Action. American Psychiatric Press, 129–177. Washington, 2000.

42. MANJI HK, LENOX RH: Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of bipolar disorder. Biol Psychiatry, 46:1328–1351, 1999.

43. MANJI KH, LENOX HR: Signaling: Cellular Insights into the Pathophysiology of Bipolar Disorder. Biol Psychiatry, 48:518-530, 2000.

44. MATUS A: Microtubule-associated proteins and neuronal morphogenesis. J Cell Sci Suppl, 15:61-67, 1991.

45. MATTSON MP: Neurotransmitters in the regulation of neuronal cytoarchitecture. Brain Res Rev, 13:179-212, 1988.

46. McEWEN BS: Stress and hippocampal plasticity. Annu Rev Neurosci, 22:105–122, 1999.

47. McEWEN BS: Possible mechanisms for atrophy of the human hippocampus. Mol Psychiatry, 2:255-262, 1997.

48. NAKAWAGA S, KIM J-E, LEE R, MALBERG JE y cols.: Regulation of neurogenesis in adult mouse hippocampus by cAMP and cAMP response element-binding protein. J Neurosci, 22:3673–3682, 2002.

49. PALAZIDOU E, SKENE D, EVERITT B, CHECKLEY SA: The acute and chronic effects of (+) and (-) oxaprotiline upon melatonin secretion in normal subjects. Psychol Med, 22:61–67, 1992.

50. ALMER TD, WILLHOITE AR, GAGE FH: Vascular niche for adult hippocampal neurogenesis. J Comp Neurol, 425:479–494, 2000.

51. EI Q, SPRAKES M, MILLAN JM, ROCHAT C, SHARP T: Erratum to “The novel monoamine reuptake inhibitor and potential antidepressant, S33005, induces Arc gene expression in cerebral cortex”. Eur J Pharmacol, 489:179-185, 2004.

52. EI Q, ZETTERSTRÖM TSC, SPRAKES M, TORDERA R, SHARP T: Antidepressant drug treatment induces Arc gene expression in the rat brain. Neuroscience, 121:975-982, 2003.

53. PEVELER R, CARSON A, RODIN G: Depression in medical patients. BMJ, 325:149-152,2002.

54. POPOLI M, BRUNELLO N, PEREZ J, RACAGNI G: Second messenger-regulated protein kinases in the brain: Their functional role and the action of antidepressant drugs. J Neurochem, 74:21–33, 2000.

55. POSNER MI, PETERSEN SE: The attention system of the human brain. Ann Rev Neurosc, 13:25-42, 1990.

56. RAJKOWSKA G: Dysfunction in neural circuits involved in the pathophysiology of mood disorders: Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry, 48:766-777, 2000.

57. AJKOWSKA G, MIGUEL-HIDALGO JJ, WEI J, DILLEY G, PITTMAN SD, MELTZER HY: Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry, 45:1085–1098, 1999.

58. RAJKOWSKA G, HALARIS A, SELEMON DL: Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry, 49:741-752, 2001.

59. REINES A, CERESETO M, FERRERO A, BONAVITA C, WIKINSKI S: Neuronal cytoskeletal alterations in an experimental model of depression. Neuroscience, 129:529–538, 2004.

60. REINSCH SS, MITCHISON TJ, KIRSCHENER M: Microtubule polymer assembly and transport during axonal elongation. J Cell Biol, 115:365-379, 1991.

61. SANTARELLI L, SAXE M, GROSS C, SURGET A y cols.: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 301:805–809, 2003.

62. SANTOS DA SILVA J, DOTTI CG: Breaking the neuronal sphere: Regulation of the actin cytoskeleton in neuritogenesis. Nature Rev Neurosci, 3:694-704. 2002.

63. SAPOLSKY RM, STEIN-BEHRENS BA, ARMANINI MP: Long-term adrenalectomy causes loss of dentate gyrus and pyramidal neurons in the adult hippocampus. Exp Neurol, 114:246-249, 1991.

64. SAPOLSKY RM, UNO H, REBERT CS, FINCH CE: Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosc, 10:2897-2902, 1990.

65. SEEDS NW, MACCIONI RB: Proteins from morphologically differentiated neuroblastoma cells promote tubulin polymerization. J Cell Biol, 76:547-555, 1978.

66. SHELINE Y, SANGHAVI M, MINTUN MA, GADO M: Depression duration but not age predicted hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosc, 19:5034-5043, 1999.

67. SKENE DJ, BOJKOWSKI CJ, ARENDT J: Comparison of the effects of acute fuvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol, 37:181–186, 1994.

68. STANLEY M, BROWN GM: Melatonin levels are reduced in the pineal glands of suicide victims. Psychopharmacol Bull, 24:484–488, 1988.

69. STOCKMEIER AC, MAHAJAN JG, KONICK CL, OVERHOLSER CJ y cols.: Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry, 56:640-650, 2004.

70. AN DX, MANCHESTER LC, HARDELAND R, LOPEZBURILLO S y cols.: Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res, 34:75-78, 2003.

71. THOMPSON C, FRANEY C, ARENDT J, CHECKLEY SA: A comparison of melatonin secretion in depressed patients and normal subjects. Br J Psychiatry, 152:260–265, 1988.

72. TRIFARO JM, VITALE ML: Cytoskeleton dynamics during neurotransmitter release. TINS, 16:466-472, 1993.

73. VAIDYA VA, SIUCIAK JA, DU F, DUMAN RS: Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience, 89:157-166, 1999.

74. WANG H, OLSEN RW: Binding of the GABA(A) receptorassociated protein (GABARAP) to microtubules and microfilaments suggests involvement of the cytoskeleton in GABARAP-GABA(A) receptor interaction. J Neurochem, 75:644-655, 2000.

75. WILLIAMS RSB, CHENG L, MUDGE, AW, HARWOOD, ADRIAN J: A common mechanism of action for three moodstabilizing drugs. Nature, 417(6886):292-295, 2002.

76. XU H, HE J, RICHARDSON JS, LI XM: The response of synaptophysin and microtubule-associated protein 1 to restraint stress in rat hippocampus and its modulation by venlafaxine. J Neurochemistry, 91(6):1380-1388, 2004.

77. YU X, MALENKA RC: Beta-catenin is critical for dendritic morphogenesis. Nat Neurosci, 6:1169-1177, 2003.